Biogen
NEWS
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
A new, 64-page study that has not been peer-reviewed, extrapolates the number of infections that stemmed from the company’s corporate meeting held at the Marriott Long Wharf hotel in February.
Biogen recently announced plans to initiate a Phase IV clinical trial to determine the benefit of Spinraza in patients who received Zolgensma. The two therapies have markedly different ways of treating the disease.
The FDA set a PDUFA target date of March 7, 2021 for aducanumab, Biogen said.
Biogen and Denali Therapeutics inked a binding deal to co-develop and co-commercialize Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease.
It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look.
Biogen announced on Wednesday that it has seen positive results from its Phase I/II study of tofersen, also known as BIIB067, for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).
Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates.
The submission was completed with ongoing collaboration with the FDA and include data from the Phase III EMERGE and ENGAGE trials, as well as the Phase Ib PRIME study. Biogen has also requested Priority Review.
JOBS
IN THE PRESS